Abstract: Methods and compositions for administration of genetically engineered bacteria are provided. The methods include genetically engineering bacteria, e.g, gastrointestinal bacteria to include heterologous coding sequences for one or more tumor antigens, such as tumor-associated antigens, and administration, e.g, oral administration, of the genetically engineered microbes to a subject in need thereof.

Abstract: The present invention pertains to single plasmid systems comprising sequences encoding programmable proteins, one or more guides, optionally donor polynucleotides, and optionally anti-CRISPR molecules, for gene editing. These plasmid systems allow for genomic engineering of bacterial strains that are difficult to transform and increase the efficiency of genomic engineering in tractable strains. Additionally, the single plasmids can be configured to provide for the transformation of a number of different bacterial strains using the same plasmid.

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Abstract: Methods and compositions for reducing reactivation of detoxified drugs, such as xenobiotic agents with narrow therapeutic indices, are provided. The methods include genetically engineering GI microbes in vivo or in vitro to include modifications that decrease or eliminate the presence of enzymes involved in xenobiotic metabolism, such as ?-glucuronidase enzymes. Microbes can also be genetically engineered to include a gene for a gut enzyme that provides a protective group to the xenobiotic drug in question.

Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.

Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.

Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.

Abstract: Aspects of the present disclosure relate to genetically engineered organisms useful for the diagnosis and treatment of inflammatory bowel disease.

Abstract: The disclosure relates to genetic engineered bacteria having a genetic memory circuit, compositions thereof, formulations thereof, methods of analyses and method of treatment of conditions related to the gastrointestinal tract including the mouth and the stomach.